{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T04:57:16Z","timestamp":1793422636693,"version":"4.5.0"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2019,2,22]],"date-time":"2019-02-22T00:00:00Z","timestamp":1550793600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Patients with a history of autoimmune diseases (AIDs) have not usually been included in clinical trials with immune checkpoint inhibitors.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and Methods<\/jats:title><jats:p>Consecutive patients with advanced cancer, treated with anti-programmed death-1 (PD-1) agents, were evaluated according to the presence of pre-existing AIDs. The incidence of immune-related adverse events (irAEs) and clinical outcomes were compared among subgroups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 751 patients were enrolled; median age was 69\u2009years. Primary tumors were as follows: non-small cell lung cancer, 492 (65.5%); melanoma, 159 (21.2%); kidney cancer, 94 (12.5%); and others, 6 (0.8%). Male\/female ratio was 499\/252. Eighty-five patients (11.3%) had pre-existing AIDs, further differentiated in clinically active (17.6%) and inactive (82.4%). Among patients with pre-existing AIDs, incidence of irAEs of any grade was significantly higher when compared with patients without AIDs (65.9% vs. 39.9%). At multivariate analysis, both inactive (p\u2009=\u2009.0005) and active pre-existing AIDs (p\u2009=\u2009.0162), female sex (p\u2009=\u2009.0004), and Eastern Cooperative Oncology Group Performance Status &amp;lt;2 (p\u2009=\u2009.0030) were significantly related to a higher incidence of irAEs of any grade. No significant differences were observed regarding grade 3\/4 irAEs and objective response rate among subgroups. Pre-existing AIDs were not significantly related with progression-free survival and overall survival.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This study quantifies the increased risk of developing irAEs in patients with pre-existing AIDs who had to be treated with anti-PD-1 immunotherapy. Nevertheless, the incidence of grade 3\/4 irAEs is not significantly higher when compared with control population. The finding of a greater incidence of irAEs among female patients ranks among the \u201chot topics\u201d in gender-related differences in immuno-oncology.<\/jats:p><\/jats:sec>","DOI":"10.1634\/theoncologist.2018-0618","type":"journal-article","created":{"date-parts":[[2019,2,22]],"date-time":"2019-02-22T19:55:24Z","timestamp":1550865324000},"page":"e327-e337","source":"Crossref","is-referenced-by-count":172,"title":["Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study"],"prefix":"10.1093","volume":"24","author":[{"given":"Alessio","family":"Cortellini","sequence":"first","affiliation":[{"name":"Medical Oncology, St. Salvatore Hospital, L'Aquila, Italy"},{"name":"Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastiano","family":"Buti","sequence":"additional","affiliation":[{"name":"Medical Oncology, University Hospital of Parma, Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Santini","sequence":"additional","affiliation":[{"name":"Medical Oncology, Campus Bio-Medico University, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiana","family":"Perrone","sequence":"additional","affiliation":[{"name":"Medical Oncology, University Hospital of Parma, Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Giusti","sequence":"additional","affiliation":[{"name":"Department of Clinical and Molecular Medicine, Sant'Andrea Hospital, Sapienza University of Rome, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Tiseo","sequence":"additional","affiliation":[{"name":"Medical Oncology, University Hospital of Parma, Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Bersanelli","sequence":"additional","affiliation":[{"name":"Medical Oncology, University Hospital of Parma, Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Michiara","sequence":"additional","affiliation":[{"name":"Medical Oncology, University Hospital of Parma, Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonino","family":"Grassadonia","sequence":"additional","affiliation":[{"name":"Department of Medical, Oral & Biotechnological Sciences, University G. D'Annunzio, Chieti-Pescara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Brocco","sequence":"additional","affiliation":[{"name":"Clinical Oncology Unit, S.S. Annunziata Hospital, Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Tinari","sequence":"additional","affiliation":[{"name":"Department of Medical, Oral & Biotechnological Sciences, University G. D'Annunzio, Chieti-Pescara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"De Tursi","sequence":"additional","affiliation":[{"name":"Department of Medical, Oral & Biotechnological Sciences, University G. D'Annunzio, Chieti-Pescara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Zoratto","sequence":"additional","affiliation":[{"name":"Medical Oncology, Santa Maria Goretti Hospital, Latina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enzo","family":"Veltri","sequence":"additional","affiliation":[{"name":"Medical Oncology, Santa Maria Goretti Hospital, Latina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Marconcini","sequence":"additional","affiliation":[{"name":"Department of Oncology, University Hospital of Pisa, Istituto Toscano Tumori, Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Malorgio","sequence":"additional","affiliation":[{"name":"Medical Oncology, \u201cSanto Spirito\u201d Hospital, Pescara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Garufi","sequence":"additional","affiliation":[{"name":"Medical Oncology, \u201cSanto Spirito\u201d Hospital, Pescara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Russano","sequence":"additional","affiliation":[{"name":"Medical Oncology, Campus Bio-Medico University, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Anesi","sequence":"additional","affiliation":[{"name":"Medical Oncology, Campus Bio-Medico University, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tea","family":"Zeppola","sequence":"additional","affiliation":[{"name":"Medical Oncology, Campus Bio-Medico University, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Filetti","sequence":"additional","affiliation":[{"name":"Department of Clinical and Molecular Medicine, Sant'Andrea Hospital, Sapienza University of Rome, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Marchetti","sequence":"additional","affiliation":[{"name":"Department of Clinical and Molecular Medicine, Sant'Andrea Hospital, Sapienza University of Rome, Rome, Italy"},{"name":"Istituto Dermopatico dell'Immacolata, IDI-IRCCS, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Botticelli","sequence":"additional","affiliation":[{"name":"Department of Clinical and Molecular Medicine, Sant'Andrea Hospital, Sapienza University of Rome, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gian Carlo","family":"Antonini Cappellini","sequence":"additional","affiliation":[{"name":"Istituto Dermopatico dell'Immacolata, IDI-IRCCS, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"De Galitiis","sequence":"additional","affiliation":[{"name":"Istituto Dermopatico dell'Immacolata, IDI-IRCCS, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Giuseppa","family":"Vitale","sequence":"additional","affiliation":[{"name":"Medical Oncology, University Hospital of Modena, Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Sabbatini","sequence":"additional","affiliation":[{"name":"Medical Oncology, University Hospital of Modena, Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Bracarda","sequence":"additional","affiliation":[{"name":"Medical Oncology, \u201cSanta Maria\u201d Hospital, Terni, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossana","family":"Berardi","sequence":"additional","affiliation":[{"name":"Oncology Clinic, Universit\u00e0 Politecnica delle Marche, Ospedali Riuniti di Ancona, Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Rinaldi","sequence":"additional","affiliation":[{"name":"Oncology Clinic, Universit\u00e0 Politecnica delle Marche, Ospedali Riuniti di Ancona, Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Tudini","sequence":"additional","affiliation":[{"name":"Medical Oncology, AV2 Fabriano ASUR Marche, Fabriano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa Rita","family":"Silva","sequence":"additional","affiliation":[{"name":"Medical Oncology, AV2 Fabriano ASUR Marche, Fabriano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annagrazia","family":"Pireddu","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, University Hospital of Cagliari, Cagliari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Atzori","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, University Hospital of Cagliari, Cagliari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Chiari","sequence":"additional","affiliation":[{"name":"Medical Oncology, Santa Maria della Misericordia Hospital, Perugia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biagio","family":"Ricciuti","sequence":"additional","affiliation":[{"name":"Medical Oncology, Santa Maria della Misericordia Hospital, Perugia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Iacono","sequence":"additional","affiliation":[{"name":"Pulmonary Oncology Unit, St. Camillo Forlanini Hospital, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Rita","family":"Migliorino","sequence":"additional","affiliation":[{"name":"Pulmonary Oncology Unit, St. Camillo Forlanini Hospital, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Rossi","sequence":"additional","affiliation":[{"name":"Medical Oncology, IRCCS Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giampiero","family":"Porzio","sequence":"additional","affiliation":[{"name":"Medical Oncology, St. Salvatore Hospital, L'Aquila, Italy"},{"name":"Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katia","family":"Cannita","sequence":"additional","affiliation":[{"name":"Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Ciciarelli","sequence":"additional","affiliation":[{"name":"Dermatology, San Salvatore Hospital, L'Aquila, Italy"},{"name":"Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Concetta","family":"Fargnoli","sequence":"additional","affiliation":[{"name":"Dermatology, San Salvatore Hospital, L'Aquila, Italy"},{"name":"Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo Antonio","family":"Ascierto","sequence":"additional","affiliation":[{"name":"Melanoma, Cancer Immunotherapy and Development Therapeutics Unit, Istituto Nazionale Tumori-IRCCS Fondazione \u201cG. Pascale\u201d, Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corrado","family":"Ficorella","sequence":"additional","affiliation":[{"name":"Medical Oncology, St. Salvatore Hospital, L'Aquila, Italy"},{"name":"Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,2,22]]},"reference":[{"key":"2021122507122007600_R1","first-page":"1119","article-title":"Multiple associations between a broad spectrum of autoimmune diseases, chronic inflammatory diseases and cancer","volume":"32","author":"Franks","year":"2012","journal-title":"Anticancer Res"},{"key":"2021122507122007600_R2","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1093\/annonc\/mdv623","article-title":"Management of immune checkpoint blockade dysimmune toxicities: A collaborative position paper","volume":"27","author":"Champiat","year":"2016","journal-title":"Ann Oncol"},{"key":"2021122507122007600_R3","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1001\/jamaoncol.2015.4368","article-title":"Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders","volume":"2","author":"Johnson","year":"2016","journal-title":"JAMA Oncol"},{"key":"2021122507122007600_R4","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/annonc\/mdw443","article-title":"Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab","volume":"28","author":"Menzies","year":"2017","journal-title":"Ann Oncol"},{"key":"2021122507122007600_R5","doi-asserted-by":"crossref","first-page":"121","DOI":"10.7326\/M17-2073","article-title":"Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: A systematic review","volume":"168","author":"Abdel-Wahab","year":"2018","journal-title":"Ann Intern Med"},{"key":"2021122507122007600_R6","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1200\/JCO.2017.77.0305","article-title":"Safety of programmed death-1 pathway inhibitors among patients with non-small-cell lung cancer and preexisting autoimmune disorders","volume":"36","author":"Leonardi","year":"2018","journal-title":"J Clin Oncol"},{"key":"2021122507122007600_R7","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ejca.2017.12.008","article-title":"Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease","volume":"91","author":"Danlos","year":"2018","journal-title":"Eur J Cancer"},{"key":"2021122507122007600_R8","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.juro.2013.08.049","article-title":"Bladder cancer in Spain 2011: Population-based study","volume":"191","author":"Minana","year":"2014","journal-title":"J Urol"},{"key":"2021122507122007600_R9","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1001\/jamadermatol.2013.706","article-title":"Distinctive features of melanoma and its management in elderly patients: A population-based study in France","volume":"149","author":"Ciocan","year":"2013","journal-title":"JAMA Dermatol"},{"key":"2021122507122007600_R10","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.cllc.2015.02.006","article-title":"Treatment of elderly patients with non-small-cell lung cancer: Results of an international expert panel meeting of the Italian Association of Thoracic Oncology","volume":"16","author":"Gridelli","year":"2015","journal-title":"Clin Lung Cancer"},{"issue":"suppl 1","key":"2021122507122007600_R11","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3109\/0284186X.2015.1115121","article-title":"Trends in kidney cancer among the elderly in Denmark, 1980-2012","volume":"55","author":"Azawi","year":"2016","journal-title":"Acta Oncol"},{"key":"2021122507122007600_R12","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"2021122507122007600_R13","first-page":"690","article-title":"Chi-square tests with one degree of freedom: Extensions of the Mantel-Haenszel procedure","volume":"58","author":"Mantel","year":"1963","journal-title":"J Am Stat Assoc"},{"key":"2021122507122007600_R14","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2307\/2340521","article-title":"On the interpretation of \u03c72 from contingency tables, and the calculation of P","volume":"85","author":"Fisher","year":"1992","journal-title":"J Royal Stat Soc"},{"key":"2021122507122007600_R15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/01621459.1968.11009219","article-title":"Association and estimation in contingency tables","volume":"63","author":"Mosteller","year":"1968","journal-title":"J Am Stat Assoc"},{"key":"2021122507122007600_R16","doi-asserted-by":"crossref","DOI":"10.1002\/9781118548387","volume-title":"Applied Logistic Regression","author":"Hosmer","year":"2013","edition":"3rd ed"},{"key":"2021122507122007600_R17","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation of incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"2021122507122007600_R18","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0197-2456(96)00075-X","article-title":"A note on quantifying follow-up in studies of failure time","volume":"17","author":"Schemper","year":"1996","journal-title":"Control Clin Trials"},{"key":"2021122507122007600_R19","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life tables (with discussion)","volume":"74","author":"Cox","year":"1972","journal-title":"J Royal Stat Soc Series B"},{"key":"2021122507122007600_R20","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/0167-5699(93)90244-F","article-title":"Defining criteria for autoimmune diseases (Witebsky's postulates revisited)","volume":"14","author":"Rose","year":"1993","journal-title":"Immunol Today"},{"key":"2021122507122007600_R21","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.autrev.2017.07.022","article-title":"Cancer and autoimmune diseases","volume":"16","author":"Giat","year":"2017","journal-title":"Autoimmun Rev"},{"key":"2021122507122007600_R22","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1001\/jamaoncol.2016.2238","article-title":"Prevalence of autoimmune disease among patients with lung cancer: Implications for immunotherapy treatment options","volume":"2","author":"Khan","year":"2016","journal-title":"JAMA Oncol"},{"issue":"suppl 6","key":"2021122507122007600_R23","first-page":"1077","article-title":"A meta-analysis of immune-related adverse events (irAE) of immune checkpoint inhibitors (ICI) from cancer clinical trials","volume":"27","author":"El Osta","year":"2016","journal-title":"Ann Oncol"},{"key":"2021122507122007600_R24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.critrevonc.2017.09.002","article-title":"Not all immune-checkpoint inhibitors are created equal: Meta-analysis and systematic review of immune-related adverse events in cancer trials","volume":"119","author":"El Osta","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"key":"2021122507122007600_R25","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1007\/s11096-018-0665-1","article-title":"Using a cancer registry to capture signals of adverse events following immune and targeted therapy for melanoma","volume":"40","author":"Aguiar","year":"2018","journal-title":"Int J Clin Pharm"},{"key":"2021122507122007600_R26","doi-asserted-by":"crossref","first-page":"MMT05","DOI":"10.2217\/mmt-2017-0028","article-title":"Real-world experience with pembrolizumab toxicities in advanced melanoma patients: A single-center experience in the UK","volume":"5","author":"So","year":"2018","journal-title":"Melanoma Manag"},{"key":"2021122507122007600_R27","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.lungcan.2017.11.019","article-title":"Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab","volume":"115","author":"Sato","year":"2018","journal-title":"Lung Cancer"},{"key":"2021122507122007600_R28","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1634\/theoncologist.2017-0384","article-title":"Association of immune-related adverse events with clinical benefit in patients with advanced non-small-cell lung cancer treated with nivolumab","volume":"23","author":"Toi","year":"2018","journal-title":"The Oncologist"},{"issue":"suppl 15","key":"2021122507122007600_R29","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1200\/JCO.2018.36.15_suppl.3064","article-title":"Correlation between immune-related adverse events (irAEs) and efficacy in patients with solid tumors treated with immune-checkpoints inhibitors (ICIs)","volume":"36","author":"Riudavets","year":"2018","journal-title":"J Clin Oncol"},{"key":"2021122507122007600_R30","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1200\/JCO.2017.73.2289","article-title":"Efficacy and safety outcomes in patients with advanced melanoma who discontinued treatment with nivolumab and ipilimumab because of adverse events: A pooled analysis of randomized phase II and III trials","volume":"35","author":"Schadendorf","year":"2017","journal-title":"J Clin Oncol"},{"key":"2021122507122007600_R31","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/nri.2016.90","article-title":"Sex differences in immune responses","volume":"16","author":"Klein","year":"2016","journal-title":"Nat Rev Immunol"},{"key":"2021122507122007600_R32","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1093\/annonc\/mdx818","article-title":"Immune-related adverse events of immune checkpoint inhibitors and the impact of sex-what we know and what we need to learn","volume":"29","author":"\u00d6zdemir","year":"2018","journal-title":"Ann Oncol"},{"key":"2021122507122007600_R33","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ejca.2017.07.013","article-title":"Sex differences in cancer risk and survival: A Swedish cohort study","volume":"84","author":"Radkiewicz","year":"2017","journal-title":"Eur J Cancer"},{"key":"2021122507122007600_R34","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/S1470-2045(18)30261-4","article-title":"Cancer immunotherapy efficacy and patients' sex: A systematic review and meta-analysis","volume":"19","author":"Conforti","year":"2018","journal-title":"Lancet Oncol"},{"key":"2021122507122007600_R35","doi-asserted-by":"crossref","first-page":"99336","DOI":"10.18632\/oncotarget.22242","article-title":"The sexist behaviour of immune checkpoint inhibitors in cancer therapy?","volume":"8","author":"Botticelli","year":"2017","journal-title":"Oncotarget"},{"key":"2021122507122007600_R36","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s12032-018-1194-4","article-title":"Patient performance status and cancer immunotherapy efficacy: A meta-analysis","volume":"35","author":"Bersanelli","year":"2018","journal-title":"Med Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2018-0618","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2018-0618","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/24\/6\/e327\/41918127\/oncolo_24_6_e327.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/24\/6\/e327\/41918127\/oncolo_24_6_e327.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T01:51:44Z","timestamp":1721008304000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/24\/6\/e327\/6439482"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,22]]},"references-count":36,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2019,2,22]]},"published-print":{"date-parts":[[2019,6,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2018-0618","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,6,1]]},"published":{"date-parts":[[2019,2,22]]}}}